Sugi Predict

Sugi Predict / Compounds / SCHEMBL769313

SCHEMBL769313

SCHEMBL769313

COc1ccc2c(c1)C(=O)CCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ KDM4E B2RXH2 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ HPGD P15428 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ GAA P10253 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ ALOX12 P18054 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ ABCB1 P08183 1/20 0.50
▸ AR P10275 1/20 0.50
▸ ABCG2 Q9UNQ0 1/20 0.50
▸ CYP19A1 P11511 2/20 0.49
▸ KLK7 P49862 1/20 0.48
▸ MAOB P27338 8/20 0.47
▸ HTT P42858 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ GRM5 P41594 4/20 0.46
▸ NFKB1 P19838 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29814619 0.90 NPC1 (0.52) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL8029261 0.90 NPC1 (0.52) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL67621 0.87 MAOB (0.60) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
Cyclopropane SCHEMBL28516873 0.85 MAOB (0.59) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL13424153 0.85 MAOB (0.66) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL172911 0.83 MAPT (0.63) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL6836610 0.83 MAOB (0.53) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL6832862 0.83 ALDH1A1 (0.56) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL9688230 0.82 GRM5 (0.51) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL25889778 0.82 HTR1A (0.55) NPC1RAB9AALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479838-B2 D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-11-25 — — US disclosed
US-20250346586-A1 CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION ARTAX BIOPHARMA INC (US) 2025-11-13 — — US disclosed
WO-2025137442-A1 SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF ARTAX BIOPHARMA INC. (US) 2025-06-26 — — WO disclosed
US-12319675-B2 Chromene derivatives as inhibitors of TCR-Nck interaction ARTAX BIOPHARMA INC. (US) 2025-06-03 — — US disclosed
WO-2024140431-A1 COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF IONGEN THERAPEUTICS CO., LTD. (CN) 2024-07-04 — — WO disclosed
US-20240199592-A1 CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION ARTAX BIOPHARMA INC. 2024-06-20 — — US disclosed
EP-4055013-B1 WDR5 INHIBITORS AND MODULATORS UNIV VANDERBILT (US) 2024-03-20 — — EP disclosed
CN-114206443-B Aromatic or heteroaromatic ring derivative and preparation method and application thereof 浙江海正药业股份有限公司 2024-02-09 — — CN disclosed
CN-117304157-A Chromene derivatives as inhibitors of TCR-NCK interactions 阿塔克斯生物制药有限公司 2023-12-29 — — CN disclosed
US-11807633-B2 Chromene derivatives as inhibitors of TCR-Nck interaction ARTAX BIOPHARMA INC. (US) 2023-11-07 — — US disclosed
US-4261988-A ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY BAYER AKTIENGESELLSCHAFT (DE) 1981-04-14 — — US disclosed
US-4258054-A ANTIDIABETIC PFIZER INC. (US) 1981-03-24 — — US disclosed
US-4210756-A Tetrahydroquinoline hydantoins for chronic diabetic complications PFIZER INC. (US) 1980-07-01 — — US disclosed
US-4209630-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1980-06-24 — — US disclosed
US-4169097-A GASTRIC ANTISECRETORY AGENTS MORTON-NORWICH PRODUCTS, INC. (US) 1979-09-25 — — US disclosed
US-4147795-A ENZYME INHIBITORS PFIZER INC. (US) 1979-04-03 — — US disclosed
US-4117230-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1978-09-26 — — US disclosed
US-4115407-A N-Benzyl-4-chromanamines MORTON-NORWICH PRODUCTS, INC. (US) 1978-09-19 — — US disclosed
US-4113743-A 2-[[6-Methoxy-(3,4-dihydro-2H-1-benzopyranyl)]amino]-1-phenylpropanol hydrochloride MORTON-NORWICH PRODUCTS. INC. (US) 1978-09-12 — — US disclosed
US-4093627-A 3-[(4-Chromanylidene)amino]-2-oxazolidinones MORTON-NORWICH PRODUCTS, INC. (US) 1978-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319675-B2 Chromene derivatives as inhibitors of TCR-Nck interaction NCK1, NCKAP1, NCKAP1L NPC1 1541/4885RAB9A 2488/4885KDM4E 3149/4885
US-20240199592-A1 CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION NCK1, NCKAP1, NCKAP1L NPC1 1541/4885RAB9A 2488/4885KDM4E 3149/4885
US-11807633-B2 Chromene derivatives as inhibitors of TCR-Nck interaction NCK1, NCKAP1, NCKAP1L NPC1 1541/4885RAB9A 2488/4885KDM4E 3149/4885
US-12479838-B2 D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof DRD3, ADRB3, VDR NPC1 2539/4885RAB9A 1364/4885KDM4E 4472/4885
US-20250346586-A1 CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION NCK1, NCKAP1, NCKAP1L NPC1 1541/4885RAB9A 2488/4885KDM4E 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.